Eledon Pharma Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
Portfolio Pulse from Benzinga Newsdesk
Eledon Pharmaceuticals (NASDAQ:ELDN) has announced the dosing of the 10th patient in its ongoing Phase 1b trial evaluating tegoprubart in kidney transplant patients. The company will report interim clinical data from this study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023.
August 16, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eledon Pharmaceuticals' ongoing Phase 1b trial of tegoprubart has reached a milestone with the dosing of the 10th patient. This could potentially impact the company's stock positively as it shows progress in their clinical trials.
The dosing of the 10th patient in Eledon's Phase 1b trial indicates progress in their clinical trials. This could potentially lead to positive investor sentiment, as it shows the company is moving forward with its product development, which could lead to future revenue growth if the drug is successful.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100